Insurance authorization takes 8–12 weeks. 30% of prescribed patients never start treatment. And now CMS requires outcomes-based payments — with five-year patient tracking that no one provides. We built the infrastructure to make it all work.
Basion is a neutral party. We don't represent manufacturers, and we don't advocate for payers. We provide infrastructure that all sides can trust.
Neutral documentation that payers actually trust
30% of prescribed patients currently never start treatment
Neither manufacturers nor states are neutral arbiters. We are.
Complete, evidence-based documentation that builds payer confidence and accelerates authorization decisions.
Our platform aggregates clinical literature, case reports, treatment guidelines, and the patient's complete medical history — producing a comprehensive briefing so patients and providers can make informed decisions about high-risk therapies.
Time-to-therapy drops from 8–12 weeks to days. More prescribed patients start treatment.
We connect to the patient's record and the insurer's requirements, identify the gap, and generate the strongest possible case for medical necessity — citing FDA labels, trial data, clinical guidelines, and patient-specific history.
CMS CGT Model compliance. Commercial outcomes-based contract administration. The neutral infrastructure that makes value-based payment possible.
For outcomes-based contracts, we provide neutral infrastructure: five-year patient tracking, multi-source data aggregation from claims, clinical registries, and patient-reported outcomes, outcome verification against contract benchmarks, and escrow services for warranty payments.
In January 2025, CMS launched the Cell and Gene Therapy Access Model — the first federal program requiring outcomes-based payments for gene therapies.
This isn't optional. If you want Medicaid to cover your gene therapy, you need this infrastructure. Legacy hubs weren't built for it.
Building evidence synthesis and outcomes tracking for rare disease requires integrating medicine, patient biology, and payer policy simultaneously. No off-the-shelf AI can do this. We built purpose-built infrastructure across four layers.
The largest structured database of the rare disease landscape: 7,000+ diseases, 800+ pharma/biotech companies, 450+ payers with coverage policies and approval precedents, 2,500+ foundations, 15,000+ specialists. When we build an authorization case, we identify similar cases that were approved, the documentation that worked, and the payer-specific requirements that applied.
Deep structured knowledge of rare disease biology: 10,000+ genes with variant annotations, 15,000+ phenotypes, 3,000+ biological pathways, 500,000+ indexed publications with extracted clinical relationships. We trace from a patient's genotype through the affected pathway to the therapeutic mechanism — providing the complete evidence picture.
Longitudinal patient models built through every interaction. Health records, patient-reported symptoms, lab trends, device data, treatment responses. This makes five-year outcomes tracking clinically meaningful — not just administrative box-checking.
50+ purpose-built AI agents across patient, caregiver, advocate, and professional use cases. Each is trained on domain-specific data and constrained to appropriate actions. The authorization agent knows which arguments work with which payers. The trial finder understands rare disease eligibility criteria.
Legacy hub services companies were built for specialty drugs — they bill for nurse hours and phone calls. That model breaks at multi-million dollar gene therapies with five-year outcome warranties.
We design patient services infrastructure during BLA preparation — so it's operational at approval, not months after. We begin building the evidence base, mapping the payer landscape, and preparing authorization protocols for your specific therapy.
Evidence synthesis and authorization services that recover patients lost to administrative friction. Our platform builds the strongest possible case for medical necessity, informed by clinical data, payer-specific requirements, and similar approved cases.
Outcomes tracking and escrow administration for CMS and commercial outcomes-based contracts. Five-year data collection, outcome verification against benchmarks, and warranty payment management.
Whether you're preparing for a launch, navigating the CMS CGT Model, or looking to improve patient access for an existing therapy — we'd welcome the conversation.